Lyra Therapeutics, Inc. (LYRA) has disclosed a new risk, in the Manufacturing category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lyra Therapeutics, Inc. faces significant business risks following the recent restart of manufacturing for LYR-210, primarily due to the transition from a contract manufacturing organization to an in-house facility. The company has yet to establish a commercial manufacturing capability, and ongoing reliance on outsourced services poses challenges, including potential lot failures and regulatory hurdles. Additionally, the reduction in experienced personnel after the May 2024 RIF could lead to production delays, impacting clinical and regulatory timelines. These factors, combined with potential trade disruptions, may hinder Lyra’s attractiveness to potential collaborators and affect its financial stability.
Overall, Wall Street has a Hold consensus rating on LYRA stock based on 5 Holds.
To learn more about Lyra Therapeutics, Inc.’s risk factors, click here.